UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

Corporate Presentation March 2022 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

/IKĭNG THERAPEUTICS Corporate Presentation February 2022 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2021 Earnings Conference Call February 9, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Les Sulewski - Truist Securities Joe Pantginis - HC Wainwright Jay Olson - Oppenheimer Alexandra Ramsey - William Blair Yale Jen - Laidlaw & Co. Scott Henry - Roth Capital Mike Kratky - SVB Leerin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-1073877 ( State or other jurisdict ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Matt Luchini - BMO Capital Steve Seedhouse - Raymond James Jay Olson - Oppenheimer Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Hello and welcome to the Viking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...

Corporate Presentation September 2021 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to success ...

/IKING THERAPEUTICS Corporate Presentation August 2021 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' a ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2021 Earnings Conference Call July 28, 2021 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Marianne Mancini - Chief Operating Officer Conference Call Participants Joon Lee - Truist Securities Matthew Luchini - BMO Capital Markets Steven Seedhouse - Raymond James Andy Hsieh - William Blair Jay Olson - Oppenheimer Yale Jen - Laidlaw & Company Justin Z ...